安科生物：与博生吉公司签署PA3-17注射液产品独家代理框架协议

Core Viewpoint - The company announced a strategic partnership with Boshengji to exclusively distribute the PA3-17 injection product in Greater China, enhancing its product portfolio and competitive edge in the innovative drug market [1] Group 1: Strategic Partnership - The company has signed a framework agreement for exclusive agency rights regarding the PA3-17 injection product in Greater China, which includes mainland China and Hong Kong, Macau, and Taiwan [1] - This partnership is aimed at integrating resources from both companies to enrich the product matrix [1] - The agreement has been approved by the company's board of directors and does not require shareholder approval [1] Group 2: Product Information - PA3-17 injection is the world's first CAR-T cell therapy product targeting CD7, developed by Boshengji [1] - The initial indication for PA3-17 is for the treatment of adult relapsed and refractory CD7-positive hematologic malignancies [1] - The agreement does not specify any financial details and is not expected to have a significant impact on the company's current operating performance [1]